Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer

NCT03430479 is registered in ClinicalTrials.gov with Kyoto Breast Cancer Research Network as lead sponsor.

NCT NCT03430479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03430479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Lead sponsor
Kyoto Breast Cancer Research Network
Phase
Phase 1/2
Overall status
Completed
Start date
June 22, 2017
Completion date
April 1, 2021
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer